Drug General Information (ID: DDIPUQ230M)
  Drug Name Alfuzosin Drug Info Probucol Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Antihyperammonia Agents
  Structure

 Mechanism of Alfuzosin-Probucol Interaction (Severity Level: Moderate)
     Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Alfuzosin Probucol
      Mechanism Prolong QT interval Prolong QT interval
      Key Mechanism Factor 1
Factor Name QT interval
Factor Description Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
      Mechanism Description
  • Increased risk of prolong QT interval by the combination of Alfuzosin and Probucol 

Recommended Action
      Management Caution is recommended if alfuzosin is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If taking drugs that also cause CNS or orthostatic effects (e.g., psychotropic drugs like tricyclic antidepressants, phenothiazines, and neuroleptics), patients should be made aware of the possibility of additive effects with alfuzosin and counseled to avoid activities requiring mental alertness until they know how these agents affect them.

References
1 Canadian Pharmacists Association.
2 Cerner Multum, Inc. "Australian Product Information.".
3 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4 Product Information. Uroxatral (alfuzosin). sanofi-aventis , Bridgewater, NJ.
5 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".